Cargando…

Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma

SIMPLE SUMMARY: Like in solid cancers, the process of dissemination is a critical feature of disease progression in the blood cancer multiple myeloma. At diagnosis, myeloma patients have cancer that has spread throughout the bone marrow, with patients with more disseminatory myeloma having worse out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeissig, Mara N., Zannettino, Andrew C. W., Vandyke, Kate
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761917/ https://www.ncbi.nlm.nih.gov/pubmed/33291672 http://dx.doi.org/10.3390/cancers12123643

Ejemplares similares

Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo
por: Zeissig, Mara N., et al.
Publicado: (2020)

GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice
por: Friend, Natasha, et al.
Publicado: (2020)

SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma()()
por: Noll, Jacqueline E., et al.
Publicado: (2014)

Characterization of the role of Samsn1 loss in multiple myeloma development
por: Friend, Natasha L., et al.
Publicado: (2020)

PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma
por: Noll, Jacqueline E., et al.
Publicado: (2015)

Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo
por: Clark, Kimberley C., et al.
Publicado: (2020)

Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo
por: Opperman, Khatora S., et al.
Publicado: (2019)

Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma
por: Ebert, Lisa M., et al.
Publicado: (2021)

Pericardial relapse of multiple myeloma
por: Jamison, Lee S, et al.
Publicado: (2020)

Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets
por: Petrusca, Daniela N., et al.
Publicado: (2022)

Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

The therapeutic potential of cell cycle targeting in multiple myeloma
por: Maes, Anke, et al.
Publicado: (2017)

DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment
por: Hewett, Duncan R., et al.
Publicado: (2017)

Rapidly Progressive Acute Liver Failure in Relapsed Multiple Myeloma
por: Wadehra, Anshu, et al.
Publicado: (2020)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma
por: Prabhala, Rao H., et al.
Publicado: (2015)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Cutaneous involvement in relapsed multiple myeloma
por: Salle, Valéry, et al.
Publicado: (2022)

A Focus on Relapsed Multiple Myeloma
por: Noonan, Kimberly, et al.
Publicado: (2022)

N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer
por: Mrozik, Krzysztof Marek, et al.
Publicado: (2018)

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
por: Teoh, P. J., et al.
Publicado: (2014)

Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma
por: Thomas, Alexandra L., et al.
Publicado: (2015)

LCRF‐0006, a small molecule mimetic of the N‐cadherin antagonist peptide ADH‐1, synergistically increases multiple myeloma response to bortezomib
por: Mrozik, Krzysztof M., et al.
Publicado: (2020)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
por: Bhatt, Parva, et al.
Publicado: (2023)

Skin dissemination of myeloma
por: Męcińska-Jundziłł, Kaja, et al.
Publicado: (2017)

Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma
por: Awuah, Dennis, et al.
Publicado: (2023)

Progress in multiple myeloma
por: Munker, Reinhold, et al.
Publicado: (2019)

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2023)

Circulating tumour DNA analysis in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2017)

Risk of relapse of multiple myeloma following kidney transplantation
por: Shah, Sapna, et al.
Publicado: (2019)

Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
por: Weiser Drozdkova, Denisa, et al.
Publicado: (2021)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Multiple myeloma with central nervous system relapse
por: Egan, Philip A., et al.
Publicado: (2020)

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing
por: Li, Wei, et al.
Publicado: (2023)

Nucleotide excision repair is a potential therapeutic target in multiple myeloma
por: Szalat, R, et al.
Publicado: (2018)

The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma
por: Zhu, Bingying, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_55jnp039kka6ib5h99ii0lg29m